{"url_path":"/sec/aeon/8-k/2026-05-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000043-index.html","accession_number":"0001837607-26-000043","cik":"0001837607","ticker":"AEON","issuer_name":"AEON Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000043-index.html","primary_entity_key":"0001837607","primary_entity_name":"AEON Biopharma, Inc."},"word_count":187,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n​\n\nOn May 14, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) made available in the investor relations section of its website a presentation (the “Corporate Presentation”), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.\n\nThe information from the Corporate Presentation may also be used by the management of the Company in future meetings regarding the Company. For important information about forward-looking statements in the Corporate Presentation, see the slide titled “Forward-Looking Statements” in Exhibit 99.1 attached hereto.\n\n​\n\nThe information furnished in this Item 7.01 of this Current Report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such a filing.\n\n​\n\n​\n\n​"}